Comparison of Omicron breakthrough infection mersus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
Comparison of Omicron breakthrough infection mersus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
Simple item page
Full item details
- dc.contributor.author
- Nantel, Sabryna
- Chao, Gary Y. C.
- Kurtesi, Alexandra
- Hu, Queenie
- Wood, Heidi
- Colwill, Karen
- Li, Zhijie
- Liu, Ying
- Seifried, Laurie
- Bourdin, Benoîte
- McGeer, Allison
- Hardy, William R.
- Rojas, Olga L.
- Ostrowski, Mario A.
- Brockman, Mark A.
- Piccirillo, Ciriaco A.
- Quach, Caroline
- Rini, James M.
- Gingras, Anne-Claude
- Decaluwe, Hélène
- Gommerman, Jennifer L.
- Gommerman, Jennifer L.
- dc.date.accessioned
- 2025-02-10T19:20:35Z
- dc.date.available
- 2025-02-10T19:20:35Z
- dc.date.issued
- 2023-09-29
- dc.description.abstract - en
- Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show that mild BT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary IgG and IgA levels against the Omicron Spike and enhanced reactivity to the ancestral Spike for the IgA isotype, which also reacted with SARS-CoV-1. Serum neutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for mucosal vaccines to emulate the enhanced mucosal and humoral immunity induced by Omicron without exposing individuals to the risks associated with SARS-CoV-2 infection.
- dc.description.sponsorship
- This study was supported by funding from a CoVaRR-Net Rapid Response Research Grant (MB, CP, CQ, JR, ACG, HD, JG) under CIHR Rapid Response Network to SARS-CoV-2 Variants (Funding Reference Number : FRN 175622) as well as the following grants : - Canadian Institutes of Health Research GA1-177703 (ACG), GA2-177710 (JG) and VR2172712 (CQ, HD) - Coalition for Epidemic Preparedness Innovations and Canadian Institutes of Health Research 468231 (HD) - Ontario Together COVID-19 Rapid Response 20013418 (JG) - Public Health Agency of Canada 2122-HQ-000225 (CQ, HD) and 2223-HQ-000261 (JG). The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by the Canada Foundation for Innovation, the Ontario Government, Genome Canada and Ontario Genomics (OGI-139).
- dc.identifier.doi
- https://doi.org/10.1101/2023.09.22.23295541
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3418
- dc.language.iso
- en
- dc.publisher - en
- medRxiv
- dc.relation.isreplacedby
- https://doi.org/10.1016/j.mucimm.2024.01.004
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Green
- dc.rights.openaccesslevel - fr
- Vert
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.title - en
- Comparison of Omicron breakthrough infection mersus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
- dc.type - en
- Submitted manuscript
- dc.type - fr
- Manuscrit soumis
- local.pagination
- 1-40
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: nantel-omicron-breakthrough-infection-monovalent-sars-cov-2-intramuscular-booster.pdf
Size: 1.46 MB
Format: PDF
Collection(s)